Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Evaluation of potential cytotoxic and apoptotic effects of paclitaxel and docetaxel in human Burkitt lymphoma cell lines

Ahmet Altun¹ , Mustafa Karademir², Gulsah Altun³

¹Department of Pharmacology, Medical Faculty, Sivas Cumhuriyet University, Turkey; ²Department of Neurosurgery, Medical Faculty, Sivas Cumhuriyet University, Turkey; ³Department of Internal Medicine, Sivas State Hospital, Sivas, Turkey.

For correspondence:- Ahmet Altun Email: md.ahmetaltun@gmail.com Tel:+905413817331

Accepted: 30 October 2022 Published: 30 November 2022

Citation: Altun A, Karademir M, Altun G. Evaluation of potential cytotoxic and apoptotic effects of paclitaxel and docetaxel in human Burkitt lymphoma cell lines. Trop J Pharm Res 2022; 21(11):2375-2378 doi: 10.4314/tjpr.v21i11.15

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the cytotoxicity of paclitaxel and docetaxel on cell viability and apoptosis in Burkitt lymphoma cell lines.

Methods: The cytotoxic activity of Paclitaxel and Docetaxel against Burkitt lymphoma cells was evaluated using the XTT cell viability test. The cells were exposed to increasing concentrations of paclitaxel and docetaxel ranging from 0.0001 to 10 µM for 48 h. Cell cycle analysis and apoptosis were also assessed using flow cytometry-based experiments.

Results: Both paclitaxel and docetaxel exhibited a concentration-dependent cytotoxic effect with IC₅₀ of 5.32 and 6.58 µM, respectively. Furthermore, paclitaxel and docetaxel were shown to have a significant apoptotic effect on Burkitt lymphoma cells (p < 0.01). Furthermore, paclitaxel and docetaxel arrested Burkitt lymphoma cells at the G2/M phase.

Conclusion: Paclitaxel and docetaxel are potential candidates for the treatment of Burkitt lymphoma. Since both drugs are already licensed for many indications, the addition of Burkitt lymphoma to the list of indications of these drugs would be a much easier and faster process. However, there is a need for further in vitro and in vivo research to fully elucidate their mechanisms of action.

Keywords: Burkitt lymphoma, Paclitaxel, Docetaxel, Apoptosis, Cytotoxicity